Literature DB >> 33482772

4'-O-Methylbroussochalcone B as a novel tubulin polymerization inhibitor suppressed the proliferation and migration of acute myeloid leukaemia cells.

Ziying Liu1, Changshui Wang2, Yali Wang2, Lei Wang2, Yueyuan Zhang2, Genquan Yan3.   

Abstract

BACKGROUND: Recent years, survival rates of human with high-risk acute myeloid leukaemia (AML) have not raised substantially. This research aimed to investigate the role of 4'-O-Methylbroussochalcone B, for the treatment of human AML.
METHODS: Firstly, we evaluated the effects of six chalcones on AML cells activity by MTT assay. Immunofluorescence staining, tubulin polymerization assay and N,N'-ethylenebis (iodoacetamide) (EBI) competition assay were performed on ML-2 cells. Transwell and apoptosis assay were also utilized in ML-2 cells and OCI-AML5 cells. The expressions of migration-related proteins, apoptosis-related proteins and Wnt/β-catenin pathway were detected by Western Blot.
RESULTS: The results found six chalcones exhibited the anti-proliferative activity against different AML cell lines. Based on the results of immunofluorescence staining, tubulin polymerization assay and EBI competition assay, 4'-O-Methylbroussochalcone B was discovered to be a novel colchicine site tubulin polymerization inhibitor. 4'-O-Methylbroussochalcone B could induce apoptosis, inhibit proliferation and migration of ML-2 cells and OCI-AML5 cells. The cells were arrested in the G2-M phase by the treatment of 4'-O-Methylbroussochalcone B. In addition, 4'-O-Methylbroussochalcone B regulated MAPK and Wnt/β-catenin pathways in AML cells.
CONCLUSION: 4'-O-Methylbroussochalcone B might inhibit proliferation and migration of the AML cells by MAPK and Wnt/β-catenin pathways as a tubulin polymerization inhibitor. It is promising for 4'-O-Methylbroussochalcone B to become a new drug to treat AML.

Entities:  

Keywords:  4′-O-Methylbroussochalcone B; Acute myeloid leukaemia; Colchicine; Migration; Tubulin polymerization inhibitor

Mesh:

Substances:

Year:  2021        PMID: 33482772      PMCID: PMC7825173          DOI: 10.1186/s12885-020-07759-4

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  33 in total

Review 1.  The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications.

Authors:  Bénédicte Delire; Peter Stärkel
Journal:  Eur J Clin Invest       Date:  2015-05-11       Impact factor: 4.686

2.  Synthesis and biological evaluation of indole-2-carbohydrazides and thiazolidinyl-indole-2-carboxamides as potent tubulin polymerization inhibitors.

Authors:  Fusun Kazan; Z Begum Yagci; Ruoli Bai; Elif Ozkirimli; Ernest Hamel; Sumru Ozkirimli
Journal:  Comput Biol Chem       Date:  2019-05-11       Impact factor: 2.877

3.  Dysregulated expression of ACTN4 contributes to endothelial cell injury via the activation of the p38-MAPK/p53 apoptosis pathway in preeclampsia.

Authors:  Jianlin Zhao; Wei Peng; Yuxin Ran; Huisheng Ge; Chen Zhang; Hong Zou; Yubin Ding; Hongbo Qi
Journal:  J Physiol Biochem       Date:  2019-08-10       Impact factor: 4.158

4.  Synthesis and evaluation of a series of resveratrol analogues as potent anti-cancer agents that target tubulin.

Authors:  Nikhil R Madadi; Hongliang Zong; Amit Ketkar; Chen Zheng; Narsimha R Penthala; Venumadhav Janganati; Shobanbabu Bommagani; Robert L Eoff; Monica L Guzman; Peter A Crooks
Journal:  Medchemcomm       Date:  2015-05-01       Impact factor: 3.597

Review 5.  Anticancer Natural Coumarins as Lead Compounds for the Discovery of New Drugs.

Authors:  Diana C G A Pinto; Artur M S Silva
Journal:  Curr Top Med Chem       Date:  2017       Impact factor: 3.295

Review 6.  Advances in targeted therapy for acute myeloid leukaemia.

Authors:  Sabine Kayser; Mark J Levis
Journal:  Br J Haematol       Date:  2017-11-28       Impact factor: 6.998

7.  Modulation of Inducible Nitric Oxide Synthase Expression in LPS-Stimulated BV-2 Microglia by Prenylated Chalcones from Cullen corylifolium (L.) Medik. through Inhibition of I-κBα Degradation.

Authors:  Do Hee Kim; Hua Li; Yeong Eun Han; Ji Hye Jeong; Hwa Jin Lee; Jae-Ha Ryu
Journal:  Molecules       Date:  2018-01-04       Impact factor: 4.411

8.  Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants.

Authors:  Mingzhao Gao; Hongmei Zhu; Li Fu; Yun Li; Xubin Bao; Haoyu Fu; Haitian Quan; Lei Wang; Liguang Lou
Journal:  Cancer Sci       Date:  2019-08-20       Impact factor: 6.518

9.  Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function.

Authors:  I Kalhari Lindamulage; Hai-Yen Vu; Chandrabose Karthikeyan; James Knockleby; Yi-Fang Lee; Piyush Trivedi; Hoyun Lee
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

10.  Peptide microarray of pediatric acute myeloid leukemia is related to relapse and reveals involvement of DNA damage response and repair.

Authors:  Hasan Mahmud; Arja Ter Elst; Frank J G Scherpen; Tiny Meeuwsen-de Boer; Kim R Kampen; Valérie de Haas; Victor Guryev; Maikel M Peppelenbosch; Steven M Kornblau; Eveline S J M de Bont
Journal:  Oncotarget       Date:  2019-07-23
View more
  3 in total

Review 1.  Molecular Mechanisms of Antiproliferative Effects of Natural Chalcones.

Authors:  Radka Michalkova; Ladislav Mirossay; Maria Gazdova; Martin Kello; Jan Mojzis
Journal:  Cancers (Basel)       Date:  2021-05-31       Impact factor: 6.639

Review 2.  Potential Role of Colchicine in Combating COVID-19 Cytokine Storm and Its Ability to Inhibit Protease Enzyme of SARS-CoV-2 as Conferred by Molecular Docking Analysis.

Authors:  Noha A Kamel; Nasser S M Ismail; Ibrahim S Yahia; Khaled M Aboshanab
Journal:  Medicina (Kaunas)       Date:  2021-12-23       Impact factor: 2.430

3.  Programmed Cell Death Alterations Mediated by Synthetic Indole Chalcone Resulted in Cell Cycle Arrest, DNA Damage, Apoptosis and Signaling Pathway Modulations in Breast Cancer Model.

Authors:  Radka Michalkova; Martin Kello; Zuzana Kudlickova; Maria Gazdova; Ladislav Mirossay; Gabriela Mojzisova; Jan Mojzis
Journal:  Pharmaceutics       Date:  2022-02-24       Impact factor: 6.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.